Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

Main Article Content

K Gordon
RB Warren
AB Gottlieb
A Blauvelt
D Thaçi
Y Poulin
M Boehnlein
F Brock
C Arendt
K Reich

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Certolizumab, Efficacy

Abstract

Abstract not available.

References

1. Parisi R. J Invest Dermatol 2013;133:377–85

2. Certolizumab Pegol Prescribing Information. Available at http://www.accessdata.fda.gov

3. Certolizumab Pegol Summary of Product Characteristics. Available at http://www.ema.europa.eu/ema

4. Gottlieb AB. JAAD 2018;79:302–14; 5Lebwohl M. JAAD 2018;79:266–76.